论文部分内容阅读
伊布利特做为新的Ⅲ类抗心律失常药物,早在1996年欧美等国家就已投入临床使用,鉴于临床应用中获得的良好疗效,近年来,在心房颤动的治疗指南中,均把伊布利特列为不伴心衰的心房颤动转复(包括心房扑动)的I类推荐药物,甚至为首选药物。我国丰原药业生产的伊布利特在2007年获得SFDA的批准进入临床.与国外相比滞后了10年。为积极推广和提高伊布利特的临床应用水平,本刊特辟“伊布利特临床病例分享”专栏,刊登临床医生应用伊布利特治疗心律失常的典型病例、精彩病例以及应用的经验与体会.欢迎广大医务者踊跃投稿。
Ibutilide as a new class III antiarrhythmic drugs, as early as 1996, Europe and the United States and other countries have been put into clinical use, given the good clinical efficacy obtained in recent years, in the treatment of atrial fibrillation guidelines, both Ibutilide is classified as a Class I class of recommended drug for the recovery of atrial fibrillation (including atrial flutter) without heart failure and is even the drug of choice. IbuLite produced by Fengyuan Pharmaceutical in China got SFDA approval to enter the clinic in 2007. Compared with other countries, it lagged for 10 years. In order to actively promote and improve the clinical application level of ibutilide, we hereby publish the column entitled “Ibutilide Clinical Case Sharing”, which lists the typical cases, wonderful cases and applications of the clinical application of ibutilide for the treatment of arrhythmia Experience and experience. Welcome to the majority of medical staff enthusiastically submitted.